medigraphic.com

2018, Número 2

<< Anterior Siguiente >>

Rev Med Inst Mex Seguro Soc 2018; 56 (2)


MGIT y otros métodos para diagnosticar tuberculosis en un sistema hospitalario privado con baja incidencia

Guajardo-Lara CE, Saldaña-Ramírez MI, Hernández-Galván NN, Dimas-Adame MA, Ayala-Gaytán JJ, Valdovinos-Chávez SB

Idioma: Español
Referencias bibliográficas: 23
Paginas: 158-162
Archivo PDF: 326.60 Kb.


RESUMEN

Introducción: la tuberculosis (TB) aún es una amenaza para la salud pública; en 2014 causó 1.5 millones de muertes a nivel mundial. En hospitales donde la prevalencia de TB es baja, resulta conveniente evaluar la efectividad de las pruebas para diagnosticarla.
Métodos: revisamos los informes de resultados de muestras de vías respiratorias enviadas para estudios de tuberculosis de mayo de 2012 a diciembre de 2015 al laboratorio de microbiología del Sistema Tec Salud (400 camas) en el área metropolitana de Monterrey. Además de la tinción de Ziehl-Neelsen (ZN) y cultivo sólido de Lowenstein-Jensen (LJ); se realizó fluorescencia LED, cultivo en medio líquido MGIT 320 y más recientemente el Xpert MTB/RIF test.
Resultados: se cultivaron en LJ y MGIT 731 muestras de vías respiratorias de 510 pacientes; en las muestras de 50 de ellos se identificó M. tuberculosis, 49 en MGIT (98%) y 42 en LJ (84%). De las muestras correspondientes a 41 pacientes, 26 (63.4%) fueron positivas con fluoresceína, y 25 (60.9%) con ZN. En las muestras de 17 pacientes se hizo PCR en tiempo real (Xpert MTB), 13 fueron positivas (76.4%).
Conclusiones: se demuestra la utilidad del cultivo en medio liquido (MGIT) y del LJ en medio sólido; el primero, además de ser más sensible, permite acortar en forma importante los tiempos de incubación.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. World Health Organization. Global Report Tuberculosis Report 2015, 20th edition, WHO. Geneva, Switzerland: WHO; 2015.

  2. World Health Organization. Systematic screening for active tuberculosis. Principles and recommendations. Geneva, Switzerland: WHO; 2013.

  3. Flores-Ibarra AA, Ochoa-Vázquez MD, Sánchez-Tec GA. Estrategias diagnósticas aplicadas en la Clínica de Tuberculosis del Hospital General Centro Médico Nacional la Raza. Rev Med Inst Mex Seguro Soc. 2016;54(1):122-7.

  4. World Health Organization. Use of liquid TB culture and drug susceptibility testing (DST) in low and medium income settings. Summary report of the expert group meeting on the use of liquid culture media. Geneva, Switzerland: WHO; 2007.

  5. World Health Organization. Fluorescent light-emitting diode (LED) microscopy for diagnosis of tuberculosis. Policy statement. Geneva, Switzerland: WHO; 2011.

  6. World Health Organization. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system. Geneva, Switzerland: WHO; 2011.

  7. Centers for Disease Control. Laboratory manual of mycobacteria. Taipei, Taiwan: Centers for Disease Control; 2004.

  8. Fitzgerald DW, Sterling TR, Haas DW. Mycobacterium tuberculosis. En: Bennett JE, Dolan R, Blaser MJ, Eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 8th ed. Philadelphia, PA: Elsevier Churchill Livingstone; 2015: chap 251. pp. 2787- 818.

  9. Cruciani M, Scarparo C, Malena M, Bosco O, Serpelloni G, Mengoli C. Meta-analysis of BACTEC MGIT 960 and BACTEC 460 TB, with or without solid media, for detection of mycobacteria. J Clin Microbiol. 2004;42:2321-5.

  10. Tyrrell FC, Budnick GE, Elliott T, Gillim-Ross L, Hildred MV, Mahlmeister P, et al. Probability of negative Mycobacterium tuberculosis complex cultures based on time to detection of positive cultures: a multicenter evaluation of commercialbroth- based culture systems. J Clin Microbiol. 2012;50:3275-82.

  11. Moreira-Ada S, Huf G, Vieira MA, Costa PA, Aguiar F, Marsico AG, et al. Liquid vs. solid culture medium to evaluate proportion and time to change in management of suspects of tuberculosis - A pragmatic randomized trial in secondary and tertiary health care units in Brazil. PLoS One. 2015;10(6):e0127588.

  12. Kim CH, Hyun IG, Hwang YI, Kim DG, Lee CY, Lee MG, et al. Identification of Mycobacterium tuberculosis and rifampin resistance in clinical specimens using the Xpert MTB/RIF assay. Ann Clin Lab Sci. 2015;45:32-8. 2

  13. Yu MC, Chien HY, Wu M, Huang W, Kuo Y, Yu F, Jou R. Evaluation of the rapid MGIT TBc identification test for culture confirmation of Mycobacterium tuberculosis complex strain detection. J Clin Microbiol. 2011;49:802-7.

  14. Reid MJ, Shah NS. Approaches to tuberculosis screening and diagnosis in people with HIV in resource-limited settings. Lancet Infect Dis. 2009;9:173-84.

  15. World Health Organization. Framework for implementing new tuberculosis diagnostics. Geneva, Switzerland: WHO; 2010.

  16. Sohn H, Aero AD, Menzies D, Behr M, Schwartzman K, Alvarez GG, et al. Xpert MTB/RIF testing in a low tuberculosis incidence, high-resource setting: limitations in accuracy and clinical impact. Clin Infect Dis. 2014;58:970-6.

  17. Salfinger M. Molecular laboratory testing for tuberculosis: innovators, early adopters, or laggards? Clin Infect Dis. 2014;58:977-9.

  18. Pinyopornpanish K, Chaiwarith R, Pantip C, Keawvichit R, Wongworapat K, Khamnoi P, et al. Comparasion of Xpert MTB/RIF assay and the conventional sputum microscopy in detecting Mycobacterium tuberculosis in Northern Thailand. Tuberc Res Treat. 2015;571782:1-6.

  19. Marlowe EM, Novak-Weekley SM, Cumpio J, Sharp SE, Momeny MA, Babst A, et al. Evaluation of the Cepheid Xpert MTB/RIF assay for direct detection of Mycobacterium tuberculosis complex in respiratory specimens. J Clin Microbiol. 2011;49:1621-3.

  20. Centers for Disease Control and Prevention (CDC). Updated guidelines for the use of nucleic acid amplification tests in the diagnosis of tuberculosis. MMWR Morb Mortal Wkly Rep. 2009;58:7-10.

  21. Taylor Z, Nolan CM, Blumberg HM; American Thoracic Society; Centers for Disease Control and Prevention; Infectious Diseases Society of America. Controlling tuberculosis in the United States. Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America. MMWR Morb Mortal Wkly Rep. 2005;54(RR-12):1-81.

  22. Haddad MB, Mitruka K, Oeltmann JE, Johns EB, Navin TR. Characteristics of tuberculosis cases that started outbreaks in the United States, 2002-2011. Emerg Infect Dis. 2015;21:508-10.

  23. Salinas JL, Mindra G, Haddad MB, Pratt R, Price SF, Langer AJ. Leveling of Tuberculosis incidence - United States, 2013-2015. MMWR Morb Mortal Wkly Rep. 2016;65:273-8.




2020     |     www.medigraphic.com